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The purpose of this project was to examine Supply Chain Management (SCM) 
strategies that MEDIMPORT can implement to reduce the high costs and increase efficiency. 
Following a case study research, it was used data from semi-structured interviews, 
consultants with experts, observations and internal documentation from the company. 
From the analyse emerge the problems of poor transportation infrastructure 
inherent to Mozambique. The challenges of distribution and logistics conduct to 
recommendations assent to implement a new supply system model based on digitalization 
of the supply chain and introduction of an anti-counterfeit system of drugs. 
The main purpose is to improve the transparency of information across the supply 
chain allowing better decisions regarding the management of consumptions, stocks, and 
forecast. 
Is expected that efficiency increase but also revenues given the more customer-
centric approach imposed by the recommendations. 
 
 









O objetivo deste projeto passou por examinar as estratégias de gestão da cadeia de 
abastecimento que a MEDIMPORT pode implementar para reduzir os elevados custos e 
simultaneamente aumentar a eficiência. 
Na pesquisa, baseada num estudo de caso, foram utilizados dados provenientes de 
entrevistas semiestruturadas, consultas junto de especialistas, observações e documentação 
interna da empresa. 
Da análise emergem os problemas de infraestrutura de transporte precária inerente 
a Moçambique. Os desafios da distribuição e logística conduziram a recomendações 
baseadas na implementação de um novo modelo de sistema de distribuição assente na 
digitalização da cadeia de abastecimentos e na introdução de um sistema de combate à 
falsificação e fraude de medicamentos. 
O principal objetivo passa por melhorar a transparência da informação ao longo da 
cadeia de abastecimento, permitindo a tomada de melhores decisões em relação à gestão 
de consumos, stocks e previsões de consumo. 
Espera-se que a eficiência aumente, mas também as receitas, dada a abordagem mais 
centrada no cliente ditada pelas recomendações. 
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1.1. Background information 
 
SCM allows organizations to optimize the utilization of assets and resources, generate 
more profits, respond to customer demand and ultimately maximize the shareholder value. 
The supply chain in the pharmaceutical industry involves multiple connections and 
actors. Only with alignment across the supply chain is possible adequate forecasting, 
procurement, inventory and distribution management. Any link that fails compromises the 
efficiency of all the supply chain with negative impacts on product costs, quality, and 
availability (Wisner et al., 2011). 
 
1.2. Research objectives and problem statement 
 
The research project aims at first place to identify challenges in the supply chain that 
have negative impacts on a reliable and cost-efficient distribution of medicines in 
Mozambique. 
The problem statement can be expressed in the following terms: 
How can MEDIMPORT reduce the high costs associated with SCM due to inherently 
poor transportation infrastructure and simultaneously increase the efficiency and availability 
of medicines? 
 
The major objective of the present study is to propose good practices in the supply 
chain processes that can be implemented feasibly by MEDIMPORT. The desirable impact 
relies on reducing operating costs, improve profitability, and facilitate increased availability 
and distributions of medicines to retailers. 
 
1.3. Research project structure 
 
The research project is organized in five main parts: i) literature review; ii) 
methodological approach, iii) analysis of interviews and company, iv) recommendations and 
v) final remarks. 
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The literature review focused on the pharmaceutical industry, supply chain and 
distribution in Africa and particularly sub-Saharan Africa. Experts in the field were also 
consulted. The purpose was to assure that the results of the research project were aligned 
with the existing knowledge given the specificities of sub-Saharan Africa. 
Taking into consideration the nature of the research, based on a case study, it was 
used qualitative method research as a methodological approach. For the effect, several 
interviews and meetings, internal and external to the company, were made in an open and 
interactive process. The interviews were predominantly face-to-face and assumed a non-
standardized and semi-structured format. Several internal documents of the company were 
analysed as well as observation of practices in warehousing and management of inventory. 
The third part consisted in organize, analyse and interpret the information collected 
from several sources. The relevant findings were summarized. 
Based on the analyse some recommendation was developed with cover of financial, 
implementation and risk considerations. 
The research project end with final remarks and considerations. 
 
2. Literature review 
 
2.1. Process of literature research 
 
For the research was applied to a combination of two dimensions: a review of 
literature and expert consultations. For the literature review, was taken into consideration a 
list of search terms and key organizations working and producing relevant literature relative 








The documents found were quickly analysed through titles and abstracts. The 
relevant studies were then scrutinized and lead to other relevant sources. The experts 
consulted provide additional recommendations of literature. It was taken into consideration 
studies addressing the pharmaceutical supply chain and industry as well as practices of 
distribution applied in Africa and particularly in sub-Saharan Africa. 
 
2.2. Literature review: considerations 
 
Having access to better health in one of the major goals and recurrently a desirable 
outcome worldwide in terms of social and economic development (Sachs, 2001). As 
expressed in the Abuja Declaration, in April 2001, the African Union (AU) countries set a 
target of allocating at least 15 % of their annual budget to improve the health sector. 
In Mozambique, it is the State who assumes the responsibility of guaranteeing the 
right and access to health for all citizens. 
4 
 
After the independence from Portugal in 1975, the Mozambican government set up 
a National Health Service (NHS) along with designing and implement priority policies of 
pharmaceutical services, defining health as a pillar to be developed (Weimer, 2012). 
The government at that time put efforts into creating a primary health system care 
to reach the poorer population that lived in rural areas. The system had so many successes 
that the World Health Organization (WHO), cited it as a model for developing countries (Walt 
and Melamed, 1983). Almost a quarter of the State budget was dedicated to health care 
(MISAU, 2015). 
The Constitutions of 1975 clear expresses in article 89: “All citizens have the right to 
medical and health care, under the Law, as well as the duty to promote and defend public 
health” (Macuácua, 2018). The revision constitutional made in 2004 goes further in 
establishing in paragraph 5 of Article 116: “It is the State’s duty to promote, discipline and 
oversee the production, sale, and use of chemical, biological and pharmaceutical products 
and other means of treatment and diagnosis” (Macuácua, 2018). 
Medicines are health inputs that play an essential role. Nevertheless, medicines are 
a motive of conflict and tensions globally. They can be classified as a public good, alongside 
with the right to health (as expressed in the Mozambican Constitution), but on the other side, 
many times they are manufactured by private companies whose main goal is to maximize 
value to shareholders (Sachy et al., 2018). 
According to the WHO, at least one-third of the world’s population has no regular 
access to medicines (Hogerzeil and Mirza, 2011). Several reasons are explaining the lack of 
access: 
 A lot of people in developing countries do not have access to health technologies 
although there are more financial resources available and developments of new types 
of medicines (Frost and Reich, 2009). 
 The high prices of medicines put problems of affordability. This can even happen in 
urban centres like Maputo, to some segments of consumers (Russo and McPake, 
2009). 
 Ineffective and inefficient distribution network for medicines having as consequence 
poor or even unavailability of medicines to the poorest segmentation of the 
population. This is especially marked in certain areas of the world as sub-Saharan 
Africa (Yadav, 2015). In the case of Mozambique, it also needs to considerer the poor 




The distribution of medicines plays a fundamental role. Several institutions 
specializing in manufacturing, import, wholesaling, retailing and various other auxiliary 
functions need to coordinate to allow drugs being available to end patients (Sachy et al., 
2018). In the case of Mozambique, this supply chain is organized in a complex net of structural 
and institutional arrangements. 
Over time, the profession of SCM has evolved to meet the changing needs of the 
global supply chain. According to the Council of Supply Chain Management Professionals 
(CSCMP): 
“Supply chain management encompasses the planning and management of all activities 
involved in sourcing and procurement, conversion, and all logistics management activities. 
Importantly, it also includes coordination and collaboration with channel partners, which can 
be suppliers, intermediaries, third party service providers, and customers. In essence, supply 
chain management integrates supply and demand management within and across 
companies” (CSMP, 2013). 
 
The CSCMP also defines logistics management as: 
“(…) The part of supply chain management that plans, implements, and controls the 
efficient, effective forward and reverses flow and storage of goods, services and related 
information between the point of origin and the point of consumption to meet customers' 
requirement. (…) Logistics management is an integrating function, which coordinates and 
optimizes all logistics activities, as well as integrates logistics activities with other functions 
including marketing, sales manufacturing, finance, and information technology” (CSMP, 
2013). 
 
The SCM includes the logistics activities plus the coordination and collaboration of 





Figure 1: Supply Chain System: functions and cross-cutting areas 
Adapted from (giz, 2016) 
 
A logistics system includes (USAID, 2009): 
 A system capable of collecting and reporting timely logistics data to inform 
quantification, procurement, storage, and distribution. 
 An inventory control system that ensures proper management of stock levels. 
 Storage and warehousing that can store commodities so that integrity and quality are 
maintained. 
 A distribution system for efficient movement of commodities from manufacturers 
through to facilities. 
 Enough personnel trained in logistics. 
 
The primary objective of logistics is allowing availability. For this is necessary a regular 
and efficient supply of medicines. Without a proper channel of distribution, there are no 




It is also possible to evaluate the purpose of a logistic system thought customer 
expectation. The scheme “six rights of logistics” is a representation of that purpose: 
 
Figure 2: The rule of “six rights logistics” 
Adapted from (USAID, 2011) 
 
Medicine logistics systems in sub-Saharan Africa have received considerable 
attention in recent years, driven by some factors including (Yadav et al., 2011): 
 More capital invested and increased economic activity. Consequently, the medicine 
supply chain also needs to respond to this higher demand. 
 The level of stocks at the supply chain is increasing but there is no reduction in stock-
outs for end-users given all the inefficiencies along the supply chain, particularly in 
rural areas. 
 
In Mozambique, 66,6% of the population live in rural areas (INE, 2019). The challenges 
in rural areas in terms of distribution are tremendous. Some of these difficulties are related 
to the following factors (Naude and Khumalo, 2001): 
 Relatively low densities of population and economies of scale. 
 The large distances that must be traversed, mostly involving the use of poor roads or 
tracks. 
 Low rates of private vehicular mobility, tele-connectivity, and activities of 
maintenance. 
 Under-developed market facilities, storage, and other logistical infrastructure. 
 The high cost of capital putting not only limits in terms of scale but also achieving 




All this conjecture often makes logistical services extremely expensive. An 
organization can establish a competitive advantage when can position itself in the market in 
a way that differentiates from the competitors. This differentiation also provides more 
defences against its competitors. Empirical literature reveals that distribution and flexibility 
are among the competitive capabilities. (Barney, 2012) 
Applying the best practices in distribution organizations can reduce the operating 
costs associated with transportation and inventory holding, improve profitability, and 




In terms of methodology was followed a qualitative research based on open-ended 
questions. 
Following a case study approach, it was used semi-structured interviews to obtain a 
more in-depth knowledge of current practices and challenges faced by MEDIMPORT in 
distributing medicines in Mozambique. 
When considering the process of collecting data, interviews assume a major role of a 
qualitative research method based on a case study (Yin, 2014). 
The interview sessions were open to discuss all aspects that could address the 
problem statement of the research project. A guide for the interview questions can be found 
in appendix 1. The interviews were conducted with the management team. 
 
4. Analysis of the current situation 
 
The analysis comports four thematic areas: i) the macro-environment of 
Mozambique, ii) brief considerations regarding the pharmaceutical sector in Mozambique; 
iii) subsidies to the value chain of MEDIMPORT and iv) trends and market drivers that will 




4.1. Macro-environmental of Mozambique 
 
The macro-environmental factors have a profound impact on an organization’s 
performance. In the case of MEDIMPORT there are several specifies that need to be 
considered (Table II). 




After independence in 1974, Mozambique enter a civil war. In 1992, the two major 
political parties in dispute, Mozambique Liberation Front (FRELIMO, Frente de Libertação de 
Moçambique), in power since the independence, and Mozambique National Resistance 
(RENAMO, Resistência Nacional de Moçambique), signed in Roma a peace agreement. 
However, the tensions were permanent along the time. More recently, at the beginning of 
August, the two parties signed a new agreement of peace (the third in the history of the 
country). In the meanwhile, the agreement is being put in cause by some armed fractions of 
the RENAMO that contest the terms and conditions of the agreement and well the leader. 
For October of 2019 are scheduled presidential elections. A scenario of violence is not out of 
place taking into consideration the history of violence. Another source of instability is related 
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to the terrorist attacks attributed to Islamist movements in the province of Cabo Delgado, 
north of the country, were major reserves of natural gas where discovered. 
Mozambique is a low-income country with a Gross National Income (GNI) per capita 
of only 460 dollars. The projected growth of the Gross Domestic Product (GDP) is modest at 
around 2,7 % in 2019 (AfDB, 2018b). In 2016, several investigations, initiated by The Wall 
Street Journal, reveal debts hidden in public accounts of approximately 2.2 billion dollars. 
After the disclosure, some relevant and meaningful events take place. The International 
Monetary Fund (IMF) suspend the financial assistant program. Moody, Fitch and Standard 
and Poor's downgraded the credit rating due to the increased risk of default. The group of 
donors of the Mozambican State Budget decided to suspend international aid to the country. 
Mozambique dive into an economic and financial crisis with contraction of investment, GDP 
and employment. The Central Bank has implemented a restrictive monetary policy in the last 
years. Inflation was been containing around 7% with the stabilization of Metical (local 
currency). The State uses domestic financing sources leaving the private sector with limited 
access to credit. The economy is little diversified and dependent on commodities (e.g. coal 
and graphite). The country has a debt-to-GDP ratio above 100% being at high risk of debt 
distress. On the other side, Mozambique's private sector is still developing, contributing just 
to 65 % of the GDP, and is characterized by low productivity and competitiveness (ADB, 2019). 
The horizon is the production of Liquefied Natural Gas (LNG), forecasted to start in 
2022/2023, with high expectations to dynamize the economy. 
The general census of the population in 2017 reveals a population of 27.909.798 
inhabitants. Nearly 66% live in rural areas. The median age is around 17 years. The fertility 
rate remains high at 5,2 children per woman. The illiteracy rate is 39%. (INE, 2019). Although 
tertiary education has become more accessible, the quality is still a major concern impacting 
the productivity of the economy. The unemployment rate is still higher. Estimation point for 
unemployment of 21% in 2015 (AfDB, 2018b). Mozambique is one of the 10 countries in the 
world most affected by Human Immunodeficiency Virus infection and Acquired Immune 
Deficiency Syndrome (HIV/AIDS). Poverty remains a challenge. According to the last 
information collected in 2015, poverty was just bellowed 50% of the population (INE, 2015). 
The NHS is underfunded. From 2014 to 2018, the health sector has been recording an average 
allocation of 9% of the State budget, well below the 2001 Abuja Declaration goal of 
governments to allocate 15% of their budgets to health (Cavelane, 2019). 
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In the past years, the country has significantly relied on support from external 
development partners and financing to fund the health sector and to purchase medicines. 
From 2012 to 2016, external aid represents 61% in financing current expenses and almost 
75% of investment expenses in the health sector. In the last years, due to the hidden debt 
scandal, the donors have reduced the support to the State budget. Nevertheless, some 
donors have implemented their development plans aside from the Ministry of Health (MoH) 
planning (Cavelane and Mapisse, 2019). In 2013, the MoH approved a National Health Sector 
Strategic Plan (PESS, Plano Estratégico do Sector de Saúde), from 2014 to 2019, that defined 
several strategies and reforms aimed at solving the main problems in the health and 
pharmaceutical sectors. The plan has been extended in time. 
In what concerns to environment Mozambique was positioned in the first place of 
the climate risk index for 2015 (GERMANWATCH, 2017). Between March and April 2019, two 
devastating tropical cyclones (Idai and Kenneth), hit the coast of Mozambique killing 
hundreds of people. Houses and basic infrastructure were destroyed on a large scale. The 
event put millions of people without access to food and water in the region affected. The 
country is extremely vulnerable to adverse climate conditions. 
This year, Mozambique was rank 135th in the Doing Business Index, against position 
138 of the previous edition of the annual World Bank report. Myriad bureaucratic and 
infrastructure challenges, such as getting access to electricity and water, are often cited as 
barriers to doing business (Group 2019). The indicators evaluated in the Logistics 
Performance Index (LPI), Indicate Mozambique need to address the competence and quality 
of logistics services. It is recommended that companies should focus on their core business 
and consider outsourcing distribution and logistics (Arvis et al., 2018). The forum MOZEFO 
(think thank group in Mozambique) points out the lack of a strong and reliable connection 
between the north and south of the country. The communications are more horizontally 
oriented putting in contact the hinterland countries to the ports located in the Indic Ocean 
(Maputo, Beira, and Nacala). Roads do not offer the best conditions for the circulation of 
people and goods. Lack of intermodal and integration network transports and undeveloped 
rail and maritime transport. The logistics costs are extremely high and uncompetitive 
(MOZEFO, 2016). 
The regulation of pharmaceutical products is governed by Law no. 12/2017 of 8th 
September, which establishes the rules applicable to the production, distribution, use, and 
marketing of medicines, vaccines, biologic products and health products. A new price regime 
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was also approved by Ministerial Order 21/2017 of 13th March. Prices are regulated through 
a cost-plus system fixing cost and profit mark-ups for each stage of medicine distribution. The 
price of medicines is the same in all national territory. Price controls seems not to be 
completely effective due to the lack of enforcement with distortions of the prices across the 
supply chain1. 
 
4.2. Pharmaceutical sector in Mozambique: brief considerations 
 
The pharmaceutical sector in Mozambique is small. The market is evaluated in 40 
million of dollars. Several agents are involved in the sector: 
 The public sector, under the NHS and Central Medical Store (CMAM, Central de 
Medicamentos e Artigos Médicos), more geographically extensive. 
 The profitable private sector with almost exclusive presence in the urban areas and 
extremely fragmented. 
 Non-Governmental Organizations (NGOs) with strong connections to the public 
sector. 
 Traditional medicine practitioners, still widely accepted by local communities, 
offering non-allopathic medicines and complementary to conventional medicine. 
 
The relation between the different agents are highly complex and characterized by 
being: 
 Fragmented. The last information available from 2017 provided by the MoH, 
reported 136 import-wholesalers of medicines registered in the country. 
 Interdepended and extremely reliant on foreign aid. The external partners account 
for 81% of medicines funding (N’weti, 2019). 
 Overlapping. As an example, the United States Agency for International Development 
(USAID) import and distribute medicines through its channels being a competitor of 
the profitable private sector2. 
 
1 According to a pharmacist, that possesses a store in the suburbs of Maputo when the product 
does not sell, and the expiry date is close the normal practice is to decrease the price. 





Until the recent past, importation and retailing of medicines were led by MEDIMOC 
and FARMAC pharmacies, two para-statal enterprises that acted for many years as sole 
importer and distributor, respectively. MEDIMOC is presently being sell. Private companies 
will do all the importation. 
Retailers tend to divide their clientele into: 
 General population (the lower-class population) from the suburb, of limited 
willingness to pay. 
 Mozambican elite and expatriates, with a preference for branded medicines. 
 
The Government of Mozambique has acknowledged the importance of 
pharmaceutical logistics and as a part of the reform agenda for MoH, developed a Pharmacy 
and Logistics Strategic Plan (PELF, Plano Estratégico de Logística Farmacêutica). 
Pharmaceutical logistics is one of the lowest-funded areas in the health sector, 
accounting for only 7% of the total projected costs through 2019 (MISAU, 2013). 
There is public evidence of systematic stock-outs of medicines in public pharmacies 
throughout the country (Wagenaar et al., 2014). 
 
4.3. Value Chain of MEDIMPORT: subsidies 
 
The major challenge of MEDIMPORT consists of linking manufacturers and retailers 
in a short period. 
The company is vertically integrated as an importer and wholesaler. It is the first 
private entity registered in Mozambique (registration license 2). 
Relies on Third-Party Logistics (3PL) in two crucial moments: a) shipping the medicines 
to Mozambique and b) supplying to retailers located outside Maputo. 
The central warehouse and support activities (management, procurement, technical 
compliance, human resources, commercial and sales) are located at Maputo (capital of 
Mozambique). Besides the warehouse, the infrastructure is composed of three distribution 
vehicles and an Enterprise Resource Planning (ERP) provided by company PHC. 
The company is subject to strict regulations to comply with storage standards 
practices of medicines especially that require could conditions. 
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The portfolio is constituted by prestigious drug medicines, branded (AstraZeneca 
Bayer, Ben, Bial, Merck Sanofi) and generic (Bluepharma), with exclusive representation. 
MEDIMPORT sells almost exclusive in the urban areas of Maputo (representing 
around 80% of revenues), Nampula and Beira. 
The margins of the wholesales and retailers are pre-defined. In the case of the 
wholesale the price is calculated based on the Cost, Insurance and Freight (CIF), with the 
addition of bank, customs clearance, and harbour expenses, as well as other direct import 
fees charged until the distributor warehouse, until a maximum of up to 9% of the CIF price. 
The macro-environment presents to MEDIMPORT external opportunities and threats 
that is synthetized in table III and developed along the document. 




The business model of MEDIMPORT has some relevant and impactfully characteristics 
that affect the overall performance: 
 The company typically holds four months of inventory. The cost associated includes 
warehousing, capital, and obsolescence. 
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 The working capital comport two components: a) investment in inventory (four 
months) and b) credit to major retailers (30 days). The credit cycle is on average 150 
days. Moreover, there is the risk that retailers delay the payment. If the client is the 
MoH the scenario is even worst. The default of obligations is not in question, but the 
credit cycle increases significantly. It can take one year to receive the payment from 
MoH. 
 MEDIMPORT has a slow order cycle time and payment cycle, on average 9 months, 
between the purchase from manufacture and the payment from the retailer. 
The containers are ordered monthly to reduce the transport cost. 
 The payment to manufactures cannot be made in domestic currency (Metical). The 
company is exposed to exchange rate fluctuations and impacted by the financial cost 
of acquiring foreign currency. Additionally, can face limitations on overseas payment 
as a result of monetary policy restrictions. 
 
The digitalization and flux on information across the supply chain are incipient. Most 
of the retailers have poor information connectivity and lacks a truly and efficient logistics 
management information system. Ordering is made by phone or email in the case of more 
sophistication retailers. 
The company also need to address several key points: 
 The demand for medicines is unpredictable but the company must be able to supply 
retailers without requiring that they hold large inventories on-site. As expressed by a 
pharmacist, in the pharmacies located in the suburbs it is not viable to stock brands, 
as they are very expensive and will not sell. There are only cheaper drugs. If the 
pharmacy is in the city, there is no interested in stocking cheaper drugs. 
 Mechanisms to provide working capital to retailers to allow purchasing medicines 
before receiving from the final consumer. 
 Provide regular information about the medicines, not only to drug prescribers but 
also to retailers. Extend the support to retailers in commercial and sales training or 





4.4. Trends and market drivers 
 
The evolution of the pharmaceutical sector in sub-Saharan Africa will be driven by 
several factors: 
 Increased healthcare expenditure. In part due to rising consumerism of growing 
population, urbanization and emerge of a middle class (Holt et al., 2015). In 
Mozambique, a significant part of the population of the upper-middle class has been 
seeking healthcare in neighbouring South Africa. This cross-border movement is a 
clear sign that the population’s standard of living is increasing, and that demand for 
quality healthcare is higher than the supply. Predictably, new private clinics, hospital 
infrastructures in rural areas, and importation of medicines will be stimulated by this 
tendency (Pinheiro et al., 2018). The retail pharmacy Mopani, located in South Africa, 
delivers medicines in Maputo by ordering charging a delivery charge3. On the other 
side, there is a tendency to an increase in healthcare insurance coverage. 
 Shift from infectious and parasitic illnesses to noncommunicable diseases to chronic 
diseases. There will be an increasing disease burden with diabetes, cancer, 
respiratory disease and heart diseases (Silverman et al., 2019). 
 Maturing business environment: strengthening of regulatory landscape and falling of 
trade barriers (AfDB, 2018a). The integrity of products, function, and authenticity, is 
a serious and becoming even more important issue (Bale, 2005). 
 Shift towards generics. There is an increased acceptance for generics associated with 
questions of affordability. Local manufacturing is being stimulated in Africa (Dong and 
Mirza, 2016). 
 Partnerships with Government bodies. Public-Private Partnerships (PPPs) initiatives 
to increase disease awareness and foment affordable treatments. 
 Digital innovations. Development of digital Information and communications 
technology industry. Rise of e-health initiatives to bridge gaps between healthcare 
providers and patients. 
 
 
3 In Monapi Pharmacy shop located in White River (two hundred kilometres away from Maputo) 







For MEDIMPORT, expand the market in Mozambique, imply in first place the premise 
that customers have access to products. Investing in distribution becomes essential to 
capture market share and customer preference. 
Coca-Cola is an example of a company that accepted to do a high investment to make 
the product available anywhere in Africa. At some point this raised the question: if we can 
get a Coca-Cola anywhere in the world, then why not life-saving medicines? Therefore, 
emerge an initiative denominated Project Last Mile (PLM). It consists of a partnership 
between Coca-Cola Sabco (local bottler in Mozambique), Global Fund, MoH and CMAM. The 
main goal is to improve the availability of life-saving medicines in all country. For that Coca-
Cola provide expertise, systems and processes to CMAM. Now it was concluded for seven of 
the 11 provinces of the country the route-mapping and distribution optimization. The 
prevision is that at April of 2020 this process will be concluded for all country4. 
There are still huge challenges for the health and medicine sector since in 
Mozambique, since poor infrastructure, to fragmented and inefficient market and lower 
purchasing power. 
Because the market is still small, to MEDIMPORT reinforce their presence and gain a 
competitive advantage against the competitors, it is suggested that the company implement 
new distribution methods. 
The recommendation is that MEDIMPORT in a short-term implement a push supply 
system model. A pilot project in Maputo province is proposed and depending on the results 
expanding nationally sustainably and profitably. The solution takes into consideration the 
technological maturity of the country. 
In a medium-long term, with the prospects of economic growth and rising demand 
for healthcare services and medicines, is relevant to think how to optimize the value for 
shareholders because of the presence in sub-Saharan Africa. For that, two new modes of 
 
4 Information recollect in meetings with José Neves (Country Lead of PLM) and Luís Silva (external 
consultant of Global Fund). 
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entry are briefly evaluated with different levels of investment, risk and geographical 
coverage. 
Lastly is recommend an implementation of a system to tackle the problem of 
counterfeit medicines. 
 
5.2. New distribution model: push supply system model 
 
Presently MEDIMPORT uses a pull supply system model. This means that the retailers 
(pharmacies and hospitals/clinics), first launch the purchase order and just then the company 
supply the medicines. In some circumstances is the clients that get the product directly in the 
main warehouse located in Maputo. 
The pull-based supply system presents several drawbacks: 
 Non-actionable consumption data and poor forecasting of clients needs; 
 No reliable and dedicated transport; 
 Cashflow problems. 
 
Consequently, there are fluctuations in stock levels with frequent stockouts but also 
risks of over-ordering (e.g. in an emergency) in retailers. This can lead to the so-called 
"bullwhip effect". 
In the new proposed model, push supply system, MEDIMPORT is responsible to 
decide when to supply medicines to clients based on stock levels of clients, without their 
direct intervention. This is only possible if there is real-time information and communication. 
The principle behind is that Information is the heart that drives the logistic cycle. 
Better information allows collecting, organize and make better decisions about 
consumptions, stocks, shipments and other variables. 
The actionable plan includes commercials visiting each pharmacy periodically with a 
delivery car loaded with medicines. In the pharmacies, they count stock levels. If the stock of 
a certain product reaches the minimum level, an immediate reposition is made thought the 
moving warehouse. 
Moreover, data of consumption is collected and transfer to the main office. For the 




Purchase orders collected by the firm by other channels (e.g. email or phone) are 
then integrated into the system and medicines delivery according to the established routes. 
Under this design, the improvement of transparency along the supply chain is 
expected to: 
 Increase the order volumes. 
 Reduce the incidence of stockouts and over-ordering. 
 Improve the accuracy of stock level information with a more regular review of 
minimal levels. 
 Improve the forecast. 
 
It is also suggested that MEDIMPORT use: 
 WhatsApp to provide information about the products to clients. Mobile phone is well 
diffused in Mozambique. Frequently pharmacies do not have laptops or other 
electronic equipment. Vodacom, the major telecommunication operator in the 
country with a share market of approximately 50% and a global reach of 6 million 
people, is launching a free service of information regarding maternal health care and 
nutrition for babies based on products accessible for the poorest within its social 
corporate responsibility. 
Although data is protected and cannot be diffused by telecommunication operators 
is still possible to know in more details the potential market of consumers for 
medicines in the country. A simple strategy consists in asking consumers on 
WhatsApp about, for example, willingness to pay, number of medicines taken in 
average during a certain period and after completing with success the questionnaire 
reward the person with a credit recharge for mobile phone5. In addition, WhatsApp 
can be used as an interface to receive purchasing orders. 
 The service m-pesa and similar services to facilitate the payments. 
 
The digitalization will allow the supply chain to be more efficient and customer-
focused (Figure 3). 
 
 





Figure 3: New distribution model 
 
5.3. Market strategy: mode of entry 
 
When evaluating the market strategy, MEDIMPORT must take in consideration three 
factors: 
 Choice of location: regional, country or urban/rural areas. 
 Entry mode and subsequent operational strategy. 
 Portfolio selection. 
 
In what concern to the choice of location, MEDIMPORT is almost exclusive present in 
the major urban areas of Mozambique. In terms of entry mode and operational strategy, the 
company has followed a centralized decision-making structure with the implantation of a 
sales subsidiary in the country. The portfolio ranges from branded drugs to generics. 
Given the unique challenges, complexities but also the perspectives of a favourable 
evolution of the macroeconomic environment in Mozambique, it is reasonable to accept 
rethinking the entry mode in Mozambique: what kind of operations and legal form to adopt. 
Two approaches were considered implying different mobilization of resources, 
competencies but also investment and risk: 
 Complete externalization of logistics; 




5.3.1. Complete externalization of logistics 
 
Enter in a strategic partnership with a logistic company to outsource all the 
importation and distributions of medicines in Mozambique. In this scenario, MEDIMPORT 
would cooperate in marketing and sales functions. Infrastructure, technology, procurement, 
inbound and outbound logistics as well operations would become fully the responsibility of 
the logistic company. The presence of MEDIMPORT would reduce substantially. 
The shift for a complete externalization would require finding the appropriate 
partner. Factors as strategic, capability, cultural and organization fit needed to be evaluated 
(Lasserre, 2017). 
Few companies have suitable capability for adding value in a future partnership as it 
is designed in Mozambique. Companies with large experience in supplying retail pharmacies, 
private hospitals, dispensing doctors and retail health stores in South Africa do not venture 
in Mozambique. As explained by a representative of United Pharmaceutical Distributors 
(UPD)6, Mozambique have poor infrastructure representing a high risk, particularly in the last 
mile delivery costs. 
On a national level, according to an exploratory analysis, the firm Tropigalia (one of 
the market leaders in distribution), demonstrate competences to integrate a future 
partnership. The company is responsible for distributing and representing global brands (e.g. 
Unilever). According to the management team7, the company import from Portugal 
containers every week, have appropriate infrastructures, distribute to all over the country 
and have an integrated inventory management system. The business model is centred in Fast-
Moving Consumer Goods (FMCG) with complete management of the supply chain in the 
country. At the time of the meeting, it was revealed the company is evaluating the possibility 
of investing in retail health stores as importer-wholesaler. 
Given the potential high costs associated with managing a complex supply chain and 
cover all country, this entry mode might work as a mitigation factor. On the other side, there 
is less substantial control over operations. 
 
 
6 Information collected in a meeting with Rehana Landis (Exports coordinator). 
7 Meeting hold with Adolfo Correia (CEO) and Ricardo Rendeiro (CCMO). 
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5.3.2. Pharmaceutical manufacturing 
 
Developing a local production of drugs requires thinking also in location. The 
pharmaceutical market in Mozambique is still small. But at a regional level increasingly new 
opportunities arise. 
Mozambique, but also Angola, belong to the trading block Southern African 
Development Community (SADC). Only adopting a regional approach is possible to achieve 
economies of scale essential to compete on price maintaining a sustainable project. Some 
developments have occurred toward economic agreements, removal of trade tariffs, and 
harmonization of medicine registration processes. SADC is also served by several trade 
corridors facilitating the circulation of people and goods. 
Consider opening a factory is based on the premise of long-term growth prospects of 
the region, largest working-age population, faster urbanization, significant natural resources 
(e.g. oil and gas) that can stimulate economic growth, and epidemiological transition (cancer, 
diabetes and hypertension will put the biggest burden on Africa´s healthcare system 
replacing AIDS/HIV and malaria). 
The African Union (AU) developed in 2007 a Pharmaceutical Manufacturing Plan for 
Africa (PMPA) and established a Technical Committee to evaluate in more detail the 
production of drugs in Africa. 
From the research and pieces of evidence, several drawbacks must be taken into 
consideration. Issues with human resources (training and retention), no Active 
Pharmaceutical Ingredient (API) production on the continent and impact of the agreement 
on Trade-Related Aspects of Intellectual Property Rights (TRIPS) for the acquisition, irregular 
and expensive utility costs, international pricing competition and lack of investment (Berger 
et al., 2016). 
The high costs of API are a barrier to compete on price against Asian generic 
manufacturers. When thinking in portfolio segmentation NGOs can be grouped in the same 
customer segment of MoH, where price is the first criteria of procurement8. In Mozambique, 
the external partners account for around 80% of medicines funding. It is essential to explore 
the elasticity of demand and optimize the trade-off between volume and price. This model 
 
8 As expressed by Leah Hasselback (Supply Systems Strengthening Advisor at USAID). 
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requires high volume and low margins to overcome the challenge of affordability at least in 
the beginning phase. 
Another key point is ensuring good manufacturing practices and guaranty production 
of quality. This is a prerequisite for WHO prequalification status and a criterion that must be 
fulfilled in NGOs procurement. 
The access to credit in financial institutions is difficult, particularly in Mozambique. 
Besides the scarcity of funding for the private sector, the overall rates are high. The 
International Finance Corporation (IFC) can be a viable source of financing. Given the amount 
of investment involved and that the project help improving the business environment and 
the health care conditions, the institution is willing to analyse and support the project if there 
is a viable investment opportunity in more favourable conditions 9. 
Notwithstanding, some positive examples emerge in Africa. In SADC community only 
South Africa has a limited degree of API production. Is estimated that South Africa represents 
more than 70% of the total estimated production in sub -Saharan region projected in USD 1 
billion of dollars (IFC, 2008). 
Aspen Pharmacare, a vertically integrated manufacturer, is a leader of the market. 
For some time, the company partnered with GlaxoSmithKline (GSK) in product licensing 
arrangements as well as skills and equity transfer. The deal ends at 2016. The company is also 
present in other countries of the region (e.g. Botswana, Namibia or Tanzania). 
In Mozambique, there is only one considerable manufacturing company of drugs. It 
is a state-owned company (SMM - Sociedade Moçambicana de Medicamentos, S.A.). The 
company started producing in 2012 antiretroviral and other drugs to support HIV/AIDS. In 
the meanwhile, the portfolio was expanded to other kind of diseases (diabetes, hypertension, 
mental illness and inflammation). The project is an initiative of the Brazilian and Mozambican 
governments. Brazil not only transfer technology, manufacturing management, training local 
technical crew but also provide financing. The total investment was around 21,5 million 
dollars mainly financed by the Brazilian State and the private company Vale (Farmaguinhos, 
2014). In the original agreement has stated four objectives: a) expand the access to 
antiretrovirals in the country; b) build local production of generic pharmaceuticals; c) reduce 
dependence on international pharmaceutical imports and d) contribute to building local 
pharmaceutical 
 
9 As expressed by Ricardo Mota (Investment Officer for IFC based in Maputo). 
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capacity in Mozambique (Oliveira, 2013). 
The entry modes presented, complete externalization of logistics (externalization 
mode) or pharmaceutical manufacturing in Angola or Mozambique (internalization mode), 
demand an in-depth analysis that this study not cover. 
Several factors will impact the eventual choice of entry mode (Lasserre, 2017). In 
Figure 4 is synthesized some variables relevant for the process of decision grouped in four 
factors: external, internal, desired mode characteristics and transaction-specific factors. 
 
Figure 4: Factors impacting the choice of mode entry 
 
5.4. Anti-counterfeit system 
 
In low and middle income countries it is estimated that the substandard and falsified 
products represent USD 30.5 billion dollars (WHO, 2017). 
According to the Mozambican health authorities, it is estimated that 12% of the 
medicines on sale in the country are counterfeit. The National Quality Control (LNCQM, 
Laboratório Nacional de Controlo da Qualidade de Medicamentos) do not have enough 
resources (human and equipment) to handle the situation. 
The increase of counterfeit drugs is adding additional need for proof of origin and 
product traceability along the supply chain. Introducing anti-counterfeit measures will 
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generate not only strong brand loyalty but also reduce false competition and increase 
revenues. 
Investing in tracking technology can be a solution. Systems developed by companies 
such as mPedigree or Sproxil already enable the authenticity of medicines through validation 
via mobile phone. The solution is being adopted by some companies in Africa. Drugs are 
printed with a unique code disguised by a scratch-off coating. When the medicine reach 
consumers they can send a text message with the code to receive confirmation of the veracity 
of the product. 
The informal sector in Mozambique is estimated to account for 31% of the GDP 
(Medina and Schneider, 2018). The percentage of medicines counterfeit is Mozambique is 
high. It is recommended that MEDIMPORT address the problem by implementing a system 
based on a validation via mobile phone. The system in the essence is based on the same 
principles as the solutions offered by mPedigree or Sproxil, presented before, but with some 
adaptations. 
Once the medicines are imported all the boxes must have a sticker with the final price 
to the consumer. The suggestion (see Figure 5) is to take advantage of this step to impress 
also in the stick a unique code, with a brief explanation of how to confirm the veracity. 
 
Figure 5: Anti-counterfeit system 
 
Then the consumer just needs to send a Short Message Service (SMS) to a given 
number and will receive immediately also by SMS the information about the veracity of the 





6. Financial analysis 
 
6.1. New distribution model: push supply system model 
 
The financial evaluation assumes (see Appendix 2) that the introduction of a new 
supply system will increase the sales constantly over the period of analyse, from 2020 to 
2025. 
The operational costs include personal expenses (hiring of 2 drivers/commercials and 
1 warehouse keeper), selling, general & administrative expense and vehicles expenses (fuel 
and maintenance). 
The total investment of the project (vehicles, tablets, mobile phones and integration 
of information) is estimated in MZN 2,5 million of meticais. 
The complete pro-forma Profit and Loss (P&L), Free Cash-Flow (FCF) and Balance 
Sheet can be found in Appendix 3. The major figures (see Figure 6) demonstrates a Net 
Present Value (NPV) positive. The Modified Internal Rate of Return (MIRR) is greater than the 
Weighted Average Cost of Capital (WACC), meaning the launch of the project is financially 
attractive. 
Payback take place near the second year. Historically the company present high 
values of cash and cash equivalents. The investment is making with equity considering a rate 
of return required by equity investors of 25%. With the financial leverage, the financial 
indicator improves despite it is a small investment. 
 
Figure 6: Financial indicators from the new supply system model 
 
Two scenarios were built (pessimist and optimistic) to evaluate possible deviations 
from the market study and corresponding impacts to the NPV of the project (see Appendix 




6.2. Anti-counterfeit system 
 
The financial evaluation assumes (see Appendix 5) that the introduction of an anti-
counterfeit system applied to medicines will increase awareness among consumers and allow 
MEDIMPORT to capture a fragment of the counterfeit and informal market. The expectation 
is that the company capture 0,5% of the counterfeit market in the first year and increase 
smoothly that percentage along the 5 years analysis. 
The major cost refers to communication (SMS sent and received by the consumer) 
and changes in printing (for which was foreseen a small investment of 200.000 meticais). 
The complete pro-forma P&L, FCF and Balance Sheet can be found in Appendix 6. The 
major figures (see Figure 7) demonstrates an NPV positive. Payback takes place after the 
second year. 
 
Figure 7: Financial indicators from anti-counterfeit system 
 
Two scenarios were built (pessimist and optimistic) to evaluate possible deviations 
from the market study and corresponding impacts to the NPV of the project (see Appendix 
7) by changing the percentage of counterfeit market acquired. 
 
7. Implementation plan 
 
A visual representation of the implementation plan of the two recommendations 
proposed can be seen in Appendix 8. 
Concerning the implementation of the new supply system model, the process begins 
with the presentation of the program to retailers. This phase is essential. From the feedback 
28 
 
and constructive interaction, the program can be adjusted. Is essential that the value 
proposition fit the retailer's needs. 
In the meanwhile, the selection of eligible retailers can also start. The criteria for 
selection must take in consideration geographic and population coverage. 
Simultaneous is desirable to initiate the process of route mapping and optimization 
of distribution. Taking into consideration the internal knowledge of the market in Maputo 
province, external services of location intelligence can be dispensed. The three phases 
mentioned before are projected to take two months. 
The process of hiring should take place in the first month following a period of 
intensive training. The emphasis should be put in sales and management of inventory. Is 
recommended formation on-job taking advantage of the internal resources and knowledge 
(country managers and commercial of the different brand drugs). It is suggested to hire 
people with previous similar experience given the typically slow learning curve. 
The investment in infrastructure (vehicles, laptop and tablets) is expected to take a 
maximum one month in line with the integration of data in the same platform. 
Monthly should be an evaluation of the system. It is recommended to having in place 
Key Performance Indicators (KPI) to measure the performance and evolution of the different 
stages of the supply chain. The exercise of measuring the supply chain allows understanding 
how is currently performing. But most important detect where are inefficiencies and help 
managers to implement measures to improve (Aronovich et al., 2010). Appendix 9 propose 
some metrics. The selection of indicators was made by supply chain function: (1) Product 
Selection, Forecasting and Procurement; (2) Warehousing and Storage; (3) Inventory and (4) 
Distribution and Transport (USAID, 2006). For each function was elected four dimensions: 
quality, cycle time, financial and productivity (Frazelle, 2002). Nevertheless, there are always 
risks of choosing indicators that hide possible inefficiencies in the supply chain. 
After six months, the extension of the program to other provinces should be 
evaluated, particularly in Nampula where the company will open a new warehouse. 
The implementation plan for the anti-counterfeit system starts with the necessary 
approvals given by the MoH. It was established for this phase one month. After the approval 
follows the agreement with a telecommunicator operator and the printing tests. Both phases 
should take half a month. After this, the service can be launch in the market followed by a 




8. Risk management 
 
For the new supply system were identified two risks with low probability but high 
impact (see Figure 8). 
 
Figure 8: Risk management of new supply system model 
 
The first risk is associated with the adherence of retailers to the new supply system 
model. The mitigation measures consist of: 
 When presenting the system most be clear the advantages: avoid stockouts or 
overordering, reduce the cost of controlling stock and ordering, dedicated transport 
and commercial and technical assistance. The goal is to help improve the overall 
performance of the business. 
 In extremis cases for the retailers that achieve a certain volume of orders can benefit 
from medicines on a consignment basis. This improves the working capital and avoid 
the costs with medicine expiring. This nuance to the system seems not to be so 
favourable to MEDIMPORT. However, the cycle of payments has no reasons to 
increase substantially. The credit will be cut-off. Normally is it given credit period of 
30 days. On the other hand, with full control of consumption and stocks, it is possible 
to allocate medicines than don´t sell in a retailer to another. The financial interest of 




The second risk is related to the connection of data between the different devices in 
the same platform. Having the appropriate technology is vital to implement this new system. 
Otherwise, the main objective of having reliable and real-time data to take decision is 
compromised. The technology proposed is compatible with the ERP used by MEDIMPORT. 
Nevertheless, some solutions have been implemented in other African countries with 
success. Software mSupply is an interesting inventory control system, free for a single user, 
that run on a tablet or smartphone. According to Craig Drown10 the company is presently 
building a "health supply hub" that will work as a vendor managed inventory. On the other 
side mSupply carry many functions of an ERP and use a RESTful API that allows other system 
to connect. 
Relatively to the anti-counterfeit system were identified three risks with different 
probabilities and impacts (see Figure 9). 
 
Figure 9: Risk management of anti-counterfeit system 
 
The first risk, with low probability but high impact, respects to the formal 
authorization of MoH. Some similar practices have been implemented in other African 
countries. The counterfeit medicines are above all a public health matter. In the case of 
 
10 Defines itself as worker of minor miracles at mSupply. 
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resistance for acceptability is recommended to join forces with other companies that operate 
legally in the country and suffer from uncompetitive practices. 
The second risk with, with medium probably of happen but low impact, respects to 
the main goal: acquire a part of the value transacted in the counterfeit segment. It is also 
important to keep in mind that medicines in Mozambique can be sold at unit invalidating the 
utilization of the system as it is design. Although the risk is medium to high the impacts are 
low given that: 
 The cost and investment are not significant given the company´s structure. 
 Allow the company to raise awareness in consumers to the problematic of counterfeit 
medicines and increase the loyalty of the brands. 
 
To mitigate the risk is suggested to invite the media and explain the measure. 
The third risk concerns the possible attempts of fraud with high impact and 
probability. It is proposed to use a unique code in each box of medicines that once validated 
cannot be used again. 
 




Given the importance of SCM is crucial that companies apply best practices to 
overcome inefficiencies and increase profitability. Improving processes require commitment 
and investment. 
Given the context where MEDIMPORT develop activities is necessary to look at 
innovative ways of doing things. The recommendation of implementing a new supply system 
and introduce an anti-counterfeit system increase the visibility across the supply chain. Also 
address the objectives of improving efficiency and profitability. Given the more customer-
centric approach is expected to increase the brand loyalty. 
The investments are not meaningful in a short time. Given the prospects of economic 
growth and rising demand for medicines, it is recommended that MEDIMPORT rethink it´s 
business model. Two ideas emerge: complete externalization of the logistic process and 
launch of a manufacturing drug plan. The investment, risk and control are very different. This 
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way, it is recommended that the company evaluate it´s strategy to address the new 
opportunities. 
 
9.2. Research limitations 
 
The interviews were performed to the top management team of MEDIMPORT. When 
considering the challenges that importers-wholesalers face in the country it is a small sample. 
Although the company is a market leader more companies should de consulted to have a 
broader characterization of the issues affecting the distribution sector of medicines in 
Mozambique. 
Another limitation is related with access to data and information. The official 
government institutions tend not release the reports even under request. Other point is 
associated with the credibility and friability of the information that comes to public. 
The last limitation is given by the theoretical background. Should be deeper and more 
detailed. There is no relevant literature in Mozambique regarding supply chain of drugs. The 
studies that exist for sub-Sahara Africa do not often mention Mozambique. 
 
9.3. Future work 
 
The future work is to present the recommendations to the board of the company 
follow by a deeper analyse and discussion together. If approved, the different financial 
assumptions, timeline and execution should be reviews according to insights of the 
management team. Ultimately, they are the one who must implement the 
recommendations. 
It is proposed also a medium-long term revision of the strategy based in two different 
entry modes. It is recommended to develop a deeper analyse that involve technical and 
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Appendix 1.1: Interview guide for internal organization and strategy 
 
1. Does MEDIMPORT possesses information about the potential market of medicines in the 
country and market trends? 
2. How is MEDIMPORT structured/organized in the country? 
3. What is strategy of the company? 
4. Where is the main source of revenues of the company? Medicines that are sold to private 
pharmacies or public contracts? 
5. Does MEDIMPORT has certifications or awards? 
6. Does the company have partnerships in place (e.g. 3PLs, ONGs, etc.)? 
 
Appendix 1.2: Interview guide for distribution 
 
1. How is organized the process of importation? 
2. How is organized the process of distribution in the country (e.g. frequency of distribution, 
network, warehouses, type of distribution – air, land or sea, partnership)? 
3. What are the logistic challenges encountered in distributing medicines? 
4. What is the impact of distribution disruptions and logistic challenges to MEDIMPORT? 
5. Does MEDIMPORT spend considerable money in SCM related factors? Why or why not? 
6. What type of SCM practices are in place for distributing medicines in Mozambique? 
7. How are routes calculated for maximum feasibility and economy? 
 
Appendix 1.3: Interview guide for data 
 
1. What data is collected? Is possible to evaluate stock in clients? 
2. How frequently is data collected? 
3. How frequently is data used to make decisions? 
4. How long will current supplies last? When MEDIMPORT need to order more supplies? 
(Assess stock on hand - quantities of usable stock available) 
5. Where is consumption the highest? 
(Assess the quantity of stock dispensed to users or used during a period) 
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6. Are MEDIMPORT losing products from the system that require action? 
(Assess losses and adjustments) 
7. Are supplies flowing smoothly through the pipeline? Does MEDIMPORT need to adjust 
the pipeline to account for bottlenecks in the distribution system? 
8. Are any products about to expire? Should MEDIMPORT take them out of the pipeline? 










Initial project year (Year 0) 2019
Average Sales Mozambique (2016 - 2018) 623 318 188,00
% Sales Maputo 80,00%
Average Sales Maputo (2016 - 2018) 498 654 550,40
Average COGS Mozambique (2016 - 2018) 417 574 728,00
% COGS Maputo 80,00%
Average COGS Maputo (2016 - 2018) 334 059 782,40
Accounts receivables (days) / (months) 30 1,0
Accounts payables (days) / (months) 180 6,0
Inventories (days) / (months) 120 4,0
Corporate Income Tax 32,00%
Calculation of WACC
Debt as % of Investment (WD) 0,00%
Equity as % of Investment (WS) 100,00%
Nominal Cost of Debt (KD) 20,00%
Cost of Debt with Tax Effect 13,60%
Rate of Return Required by Equity Investors (KS) 25,00%
Weighted Average Cost of Capital (WACC) 25,00%
2019 2020 2021 2022 2023 2024
Growth rate of prices 5,10% 5,50% 5,50% 5,50% 5,50%
Source: African Economic Outlook (AEO) and International Monetary Fund (IMF)
2019 2020 2021 2022 2023 2024
Growth rate of sales 2,00% 4,00% 6,00% 8,00% 10,00%
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Appendix 3: New supply system model – P&L, FCF and Balance Sheet 
 
2019 2020 2021 2022 2023 2024
Sales 0,00 9 973 091,01 20 345 105,66 31 139 979,36 42 383 562,38 54 103 811,28
COGS 0,00 6 681 195,65 13 629 639,12 20 861 365,29 28 393 691,82 36 245 347,42
Gross Margin 0,00 3 291 895,36 6 715 466,53 10 278 614,07 13 989 870,57 17 858 463,86
Operational Costs 0,00 3 840 000,00 4 051 200,00 4 274 016,00 4 509 086,88 4 757 086,66
EBITDA 0,00 -548 104,64 2 664 266,53 6 004 598,07 9 480 783,69 13 101 377,20
Depreciation 0,00 500 000,00 500 000,00 500 000,00 500 000,00 500 000,00
EBIT 0,00 -1 048 104,64 2 164 266,53 5 504 598,07 8 980 783,69 12 601 377,20
Tax on Operating Profits 0,00 -335 393,48 692 565,29 1 761 471,38 2 873 850,78 4 032 440,70
Financial Charges 0,00 0,00 0,00 0,00 0,00 0,00
Other Income 0,00 0,00 0,00 0,00 0,00 0,00
Net income 0,00 -712 711,16 1 471 701,24 3 743 126,69 6 106 932,91 8 568 936,49
Operating FCF 2019 2020 2021 2022 2023 2024
Operating Results: EBIT 0,00 -1 048 104,64 2 164 266,53 5 504 598,07 8 980 783,69 12 601 377,20
Taxes on EBIT: EBIT x Corporate Income Tax 0,00 -335 393,48 692 565,29 1 761 471,38 2 873 850,78 4 032 440,70
Depreciation 0,00 500 000,00 500 000,00 500 000,00 500 000,00 500 000,00
Total 0,00 -212 711,16 1 971 701,24 4 243 126,69 6 606 932,91 9 068 936,49
Working Capital Needs 2019 2020 2021 2022 2023 2024
Receivables 0,00 831 090,92 1 695 425,47 2 594 998,28 3 531 963,53 4 508 650,94
Inventories 0,00 2 227 065,22 4 543 213,04 6 953 788,43 9 464 563,94 12 081 782,47
Payables 0,00 3 340 597,82 6 814 819,56 10 430 682,65 14 196 845,91 18 122 673,71
Working Capital Needs 0,00 -282 441,69 -576 181,05 -881 895,93 -1 200 318,44 -1 532 240,30
Changes in Working Capital 0,00 -282 441,69 -293 739,36 -305 714,89 -318 422,50 -331 921,86
Investing FCF 2019 2020 2021 2022 2023 2024
CAPEX 2 500 000,00 0,00 0,00 0,00 0,00 0,00
2019 2020 2021 2022 2023 2024
Tax on Operating Profits 0,00 -335 393,48 1 027 958,78 1 068 906,09 1 112 379,40 1 158 589,92
2019 2020 2021 2022 2023 2024
Total FCF -2 500 000,00 -265 662,95 3 293 399,38 5 617 747,67 8 037 734,81 10 559 448,28
Accumulated FCF -2 500 000,00 -2 765 662,95 527 736,43 6 145 484,10 14 183 218,90 24 742 667,18
2019 2020 2021 2022 2023 2024
Non-current Assets 2 500 000,00 2 000 000,00 1 500 000,00 1 000 000,00 500 000,00 0,00
Tangible Fixed Assets 2 500 000,00 2 000 000,00 1 500 000,00 1 000 000,00 500 000,00 0,00
Current Assets 0,00 3 058 156,13 9 532 037,89 18 459 933,76 29 945 409,32 44 098 763,54
Inventories 0,00 2 227 065,22 4 543 213,04 6 953 788,43 9 464 563,94 12 081 782,47
Receivables 0,00 831 090,92 1 695 425,47 2 594 998,28 3 531 963,53 4 508 650,94
Cash and cash equivalents 0,00 0,00 3 293 399,38 8 911 147,04 16 948 881,85 27 508 330,13
2 500 000,00 5 058 156,13 11 032 037,89 19 459 933,76 30 445 409,32 44 098 763,54
Share Capital 2 500 000,00 2 765 662,95 2 765 662,95 2 765 662,95 2 765 662,95 2 765 662,95
Undistributed profits 0,00 0,00 -712 711,16 758 990,09 4 502 116,78 10 609 049,68
Net income for the period 0,00 -712 711,16 1 471 701,24 3 743 126,69 6 106 932,91 8 568 936,49
2 500 000,00 2 052 951,79 3 524 653,04 7 267 779,73 13 374 712,63 21 943 649,13
Non-current Liabilities 0,00 0,00 0,00 0,00 0,00 0,00
Bank loans 0,00 0,00 0,00 0,00 0,00 0,00
Current Liabilities 0,00 3 005 204,34 7 507 384,85 12 192 154,03 17 070 696,69 22 155 114,41
Trade payables 0,00 3 340 597,82 6 814 819,56 10 430 682,65 14 196 845,91 18 122 673,71
State and other public entities 0,00 -335 393,48 692 565,29 1 761 471,38 2 873 850,78 4 032 440,70
0,00 3 005 204,34 7 507 384,85 12 192 154,03 17 070 696,69 22 155 114,41





Total Equity + Total Liabilities








Appendix 4: New supply system model – scenarios 
 
 
Base Scenario Pessimistic Optimistic
Variables:
Growth rate of sales: 2020 2,00% 1,00% 4,00%
Growth rate of sales: 2021 4,00% 2,00% 6,00%
Growth rate of sales: 2022 6,00% 4,00% 8,00%
Growth rate of sales: 2023 8,00% 6,00% 10,00%
Growth rate of sales: 2024 10,00% 8,00% 12,00%
Results:
NPV 9 023 908,24 2 448 359,75 16 848 481,03
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Initial project year (Year 0) 2019
Market value 2 480 000 000,00
Counterfeit market in % 12,00%
Counterfeit market in value 297 600 000,00
Number of medicine boxes sell by year 800 000,00
SMS: send (unit cost) 1,60
SMS: report (unit cost) 0,30
Other cost (priting) 0,50
Accounts receivables (days) / (months) 30 1,0
Accounts payables (days) / (months) 30 1,0
Inventories (days) / (months) 0,0
Corporate Income Tax 32,00%
Calculation of WACC
Debt as % of Investment (WD) 0,00%
Equity as % of Investment (WS) 100,00%
Nominal Cost of Debt (KD) 20,00%
Cost of Debt with Tax Effect 13,60%
Rate of Return Required by Equity Investors (KS) 25,00%
Weighted Average Cost of Capital (WACC) 25,00%
2019 2020 2021 2022 2023 2024
Growth rate of prices 5,10% 5,50% 5,50% 5,50% 5,50%
Source: African Economic Outlook (AEO) and International Monetary Fund (IMF)
2019 2020 2021 2022 2023 2024
Counterfeit market capture by MEDIMPORT in % 0,50% 1,00% 1,00% 1,50% 1,50%
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Appendix 6: Anti-counterfeit system – P&L, FCF and Balance Sheet 
 
 
2019 2020 2021 2022 2023 2024
Sales 0,00 1 488 000,00 2 976 000,00 2 976 000,00 4 464 000,00 4 464 000,00
COGS 0,00 0,00 0,00 0,00 0,00 0,00
Gross Margin 0,00 1 488 000,00 2 976 000,00 2 976 000,00 4 464 000,00 4 464 000,00
Operational Costs 0,00 2 100 000,00 2 215 500,00 2 337 352,50 2 465 906,89 2 601 531,77
EBITDA 0,00 -612 000,00 760 500,00 638 647,50 1 998 093,11 1 862 468,23
Depreciation 0,00 40 000,00 40 000,00 40 000,00 40 000,00 40 000,00
EBIT 0,00 -652 000,00 720 500,00 598 647,50 1 958 093,11 1 822 468,23
Tax on Operating Profits 0,00 -208 640,00 230 560,00 191 567,20 626 589,80 583 189,83
Financial Charges 0,00 0,00 0,00 0,00 0,00 0,00
Other Income 0,00 0,00 0,00 0,00 0,00 0,00
Net income 0,00 -443 360,00 489 940,00 407 080,30 1 331 503,32 1 239 278,40
Operating FCF 2019 2020 2021 2022 2023 2024
Operating Results: EBIT 0,00 -652 000,00 720 500,00 598 647,50 1 958 093,11 1 822 468,23
Taxes on EBIT: EBIT x Corporate Income Tax 0,00 -208 640,00 230 560,00 191 567,20 626 589,80 583 189,83
Depreciation 0,00 40 000,00 40 000,00 40 000,00 40 000,00 40 000,00
Total 0,00 -403 360,00 529 940,00 447 080,30 1 371 503,32 1 279 278,40
Working Capital Needs 2019 2020 2021 2022 2023 2024
Receivables 0,00 124 000,00 248 000,00 248 000,00 372 000,00 372 000,00
Inventories 0,00 0,00 0,00 0,00 0,00 0,00
Payables 0,00 0,00 0,00 0,00 0,00 0,00
Working Capital Needs 0,00 124 000,00 248 000,00 248 000,00 372 000,00 372 000,00
Changes in Working Capital 0,00 124 000,00 124 000,00 0,00 124 000,00 0,00
Investing FCF 2019 2020 2021 2022 2023 2024
CAPEX 200 000,00 0,00 0,00 0,00 0,00 0,00
2019 2020 2021 2022 2023 2024
Tax on Operating Profits 0,00 -208 640,00 439 200,00 -38 992,80 435 022,60 -43 399,96
2019 2020 2021 2022 2023 2024
Total FCF -200 000,00 -736 000,00 845 140,00 408 087,50 1 682 525,91 1 235 878,44
Accumulated FCF -200 000,00 -936 000,00 -90 860,00 317 227,50 1 999 753,41 3 235 631,85
2019 2020 2021 2022 2023 2024
Non-current Assets 200 000,00 160 000,00 120 000,00 80 000,00 40 000,00 0,00
Tangible Fixed Assets 200 000,00 160 000,00 120 000,00 80 000,00 40 000,00 0,00
Current Assets 0,00 124 000,00 1 093 140,00 1 501 227,50 3 307 753,41 4 543 631,85
Inventories 0,00 0,00 0,00 0,00 0,00 0,00
Receivables 0,00 124 000,00 248 000,00 248 000,00 372 000,00 372 000,00
Cash and cash equivalents 0,00 0,00 845 140,00 1 253 227,50 2 935 753,41 4 171 631,85
200 000,00 284 000,00 1 213 140,00 1 581 227,50 3 347 753,41 4 543 631,85
Share Capital 200 000,00 936 000,00 936 000,00 936 000,00 936 000,00 936 000,00
Undistributed profits 0,00 0,00 -443 360,00 46 580,00 453 660,30 1 785 163,62
Net income for the period 0,00 -443 360,00 489 940,00 407 080,30 1 331 503,32 1 239 278,40
200 000,00 492 640,00 982 580,00 1 389 660,30 2 721 163,62 3 960 442,02
Non-current L iabilities 0,00 0,00 0,00 0,00 0,00 0,00
Bank loans 0,00 0,00 0,00 0,00 0,00 0,00
Current L iabilities 0,00 -208 640,00 230 560,00 191 567,20 626 589,80 583 189,83
Trade payables 0,00 0,00 0,00 0,00 0,00 0,00
State and other public entities 0,00 -208 640,00 230 560,00 191 567,20 626 589,80 583 189,83
0,00 -208 640,00 230 560,00 191 567,20 626 589,80 583 189,83

















Base Scenario Pessimistic Optimistic
Variables:
Counterfeit market capture by MEDIMPORT in %: 2020 0,50% 0,70% 0,20%
Counterfeit market capture by MEDIMPORT in %: 2021 1,00% 1,20% 0,80%
Counterfeit market capture by MEDIMPORT in %: 2022 1,00% 1,20% 0,80%
Counterfeit market capture by MEDIMPORT in %: 2023 1,50% 1,70% 1,30%
Counterfeit market capture by MEDIMPORT in %: 2024 1,50% 1,70% 1,30%
Results:
NPV 1 055 165,66 2 256 305,29 -319 137,49 
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Appendix 9: Supply Chain Management – Performance Measures 
 
 Quality Measures Cycle Time Measures Financial Measures Productivity Measures 
Product Selection / 
Forecasting / Procurement 
Forecast Accuracy Total Purchase Order Cycle 
Time 
Profit Margin Supplier Fill Rate 
Warehousing / Storage Inventory Accuracy Rate Customs Clearance Cycle Total Warehousing Cost Storage Space Utilization 
Inventory Plan in Place for Predictable 
Change in Demand 
Order Lead Time Value of Unusable Stock Inventory Velocity 
Distribution / Transport On-Time Arrivals 
Percentage of Shipments 
where Quantity Dispatched 
Equals Quantity Received 
Percentage of Shipments 
Arriving in Good Conditions 
Average Delivery Time Total Transportation Cost 
Ratio of Transportation Cost 
to Value of Product 
Average Number of Stops 
per Route 
 
